Reviva Pharmaceuticals Holdings Inc（RVPH）财务数据RVPHReviva Pharmaceuticals Holdings Inc

Evaluating the bottom line, Reviva Pharmaceuticals Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -256.20%, provide a clear picture of how effectively RVPH converts its operational activities into shareholder value.

In the context of the broader market, RVPH competes directly with industry leaders such as CLRB and CDT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, RVPH's gross margin of N/A stands against CLRB's N/A and CDT's N/A. Such benchmarking helps identify whether Reviva Pharmaceuticals Holdings Inc is trading at a premium or discount relative to its financial performance.

Latest quarter: Q1 2026. Reviva reported GAAP EPS of -$0.46, missing expectations by $0.11. Net loss improved to approximately $3.2 million from $6.4 million in Q1 2025, which is a year-over-year improvement in losses, but profitability is still absent. Cash rose to approximately $22.2 million as of March 31, 2026, helped by the March equity offering, yet the news flow shows continued need for capital, which weakens the long-term investment case for a beginner investor.